Your browser is no longer supported. Please, upgrade your browser.
Settings
NTEC Intec Pharma Ltd. daily Stock Chart
NTEC [NASD]
Intec Pharma Ltd.
Index- P/E- EPS (ttm)-1.10 Insider Own10.19% Shs Outstand69.27M Perf Week0.07%
Market Cap20.07M Forward P/E- EPS next Y-0.12 Insider Trans-11.49% Shs Float56.40M Perf Month-30.95%
Income- PEG- EPS next Q-0.05 Inst Own17.02% Short Float5.09% Perf Quarter54.64%
Sales- P/S- EPS this Y83.70% Inst Trans- Short Ratio0.36 Perf Half Y-41.69%
Book/sh0.27 P/B1.08 EPS next Y47.80% ROA- Target Price- Perf Year-92.64%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.13 - 4.36 Perf YTD-42.04%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-93.36% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low118.86% ATR0.04
Employees38 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)45.88 Volatility6.50% 10.79%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.26 Prev Close0.28
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume8.03M Price0.29
Recom3.00 SMA20-14.95% SMA50-2.16% SMA200-32.83% Volume2,075,161 Change2.77%
Oct-11-19Downgrade ROTH Capital Buy → Neutral $10 → $1
Mar-26-18Reiterated Maxim Group Buy $8 → $12
Feb-28-18Initiated Ladenburg Thalmann Buy
Feb-26-18Initiated H.C. Wainwright Buy
Sep-21-17Reiterated Oppenheimer Outperform $10 → $15
Sep-16-15Initiated Maxim Group Buy $9
Sep-11-15Initiated ROTH Capital Buy $9.50
Jun-13-20 09:04AM  
Jun-05-20 12:00PM  
Jun-02-20 10:03AM  
May-28-20 08:00AM  
May-11-20 04:15PM  
May-04-20 03:33PM  
08:11AM  
Mar-26-20 01:05PM  
Mar-13-20 07:30AM  
Feb-25-20 07:30AM  
Jan-30-20 10:44PM  
04:11PM  
Jan-09-20 07:00AM  
Dec-23-19 07:51PM  
Dec-11-19 07:30AM  
Dec-06-19 07:30AM  
Dec-03-19 07:30AM  
Nov-13-19 07:00AM  
Nov-12-19 07:00AM  
Sep-25-19 07:00AM  
Sep-16-19 07:00AM  
Sep-03-19 07:00AM  
Aug-30-19 11:28AM  
08:52AM  
Aug-13-19 10:09AM  
Aug-09-19 07:00AM  
Aug-06-19 12:00PM  
Jul-22-19 10:15AM  
08:56AM  
07:00AM  
Jul-03-19 05:00PM  
Jul-01-19 09:00AM  
Jun-28-19 05:45PM  
Jun-25-19 07:00AM  
Jun-19-19 07:00AM  
May-28-19 07:00AM  
May-20-19 07:00AM  
May-16-19 06:00AM  
May-07-19 07:00AM  
May-02-19 07:00AM  
Apr-30-19 07:00AM  
Apr-24-19 11:30AM  
Apr-01-19 07:00AM  
Mar-27-19 06:00AM  
Mar-13-19 07:00AM  
Feb-28-19 09:42AM  
Feb-27-19 07:00AM  
Feb-20-19 10:03AM  
Feb-19-19 07:00AM  
Jan-04-19 07:00AM  
Jan-02-19 07:00AM  
Dec-23-18 02:39AM  
Dec-19-18 09:28AM  
Dec-13-18 09:15AM  
Dec-11-18 10:37AM  
Dec-06-18 07:00AM  
Dec-03-18 06:50AM  
Nov-21-18 08:55AM  
Nov-09-18 07:00AM  
Nov-07-18 09:43AM  
Nov-06-18 07:00AM  
Nov-02-18 12:15PM  
Oct-22-18 07:00AM  
Sep-25-18 07:00AM  
Sep-20-18 07:00AM  
Aug-15-18 07:30AM  
Jul-20-18 06:00AM  
Jun-29-18 07:00AM  
May-31-18 08:30AM  
May-15-18 07:00AM  
Apr-26-18 07:40AM  
Apr-24-18 07:00AM  
Apr-13-18 04:01PM  
Apr-11-18 09:00AM  
Apr-10-18 04:01PM  
10:00AM  
Apr-04-18 08:00AM  
Apr-03-18 08:00AM  
Mar-26-18 07:00AM  
Mar-12-18 04:30PM  
Mar-09-18 07:00AM  
Mar-05-18 07:15AM  
Jan-31-18 08:00AM  
Jan-08-18 08:00AM  
Jan-06-18 03:23PM  
Jan-03-18 08:00AM  
Nov-15-17 04:01PM  
Nov-08-17 08:00AM  
Nov-01-17 07:00AM  
07:00AM  
Oct-26-17 07:00AM  
Oct-06-17 07:00AM  
Sep-29-17 05:18PM  
Sep-20-17 07:00AM  
Sep-08-17 10:38AM  
Sep-01-17 08:00AM  
Aug-22-17 08:15AM  
Aug-21-17 04:15PM  
Aug-16-17 09:00AM  
Aug-15-17 04:01PM  
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various indications, including low back pain, neuropathic pain, and fibromyalgia. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dexcel Pharma Technologies Ltd10% OwnerFeb 04Sale0.29110,00031,9004,234,897Feb 04 06:41 PM
Dexcel Pharma Technologies Ltd10% OwnerFeb 03Sale0.3280,00025,4404,344,897Feb 04 06:41 PM
Dexcel Pharma Technologies Ltd10% OwnerJan 31Sale0.31725,951224,3194,424,897Feb 04 06:41 PM
Meckler Jeffrey AChief Executive OfficerAug 28Buy0.6820,00013,620196,761Aug 29 04:16 PM
MADDALUNA ANTHONY JDirectorAug 27Buy0.4725,00011,75053,570Aug 29 04:16 PM
KOZARICH JOHN WDirectorAug 23Buy0.46100,00045,900151,761Aug 27 04:20 PM
Meckler Jeffrey AChief Executive OfficerAug 23Buy0.46100,00045,700176,761Aug 27 04:18 PM